Skip to main content

Table 3 Results of SPARC genotyping analysis in AML samples.

From: In silico whole-genome screening for cancer-related single-nucleotide polymorphisms located in human mRNA untranslated regions

   AML patients Healthy donors OR (95% CI)
SNP 1474 GG 13 20  
  GA 0 0  
  AA 0 0  
  Allelic Frequency A (%)    
SNP 1551 GG 2 7  
  GC 8 7  
  CC 3 6  
  Allelic Frequency C (%) 53 47 2.9 (0.5–17.3)
SNP 1922 TT 13 5  
  TG 2 1  
  GG 0 0  
  Allelic Frequency G (%) 13   0.8 (0.05–10.5)
SNP 2072 CC 4 10  
  CT 7 3  
  TT 4 4  
  Allelic Frequency T (%) 50 32 3.9 (0.9–17.5)
SNP 2168 GG 3 11  
  GA 6 1  
  AA 4 5  
  Allelic Frequency A (%) 54 32 6.1 (1.2–31.2)
  1. AML: acute myeloblastic leukaemia; OR: odds ratio; CI: confidence interval.